GICC Holdings

GICC Holdings is a clinical-stage biotechnology company specializing in the development of advanced cancer immunotherapies, particularly CAR-T and TCR-T cell therapies. Operating through its subsidiaries, including GICC Biotech and the Global Immunotherapy Cancer Center, the company focuses on treating both hematological malignancies and refractory solid tumors. Their pipeline includes candidates targeting CD19 and BCMA for blood cancers, as well as GPC3 and Mesothelin for solid tumors like liver and pancreatic cancer. GICC integrates a comprehensive approach that spans from basic research and genetic engineering to clinical application and personalized patient care. The company maintains a global presence with facilities in the United States and China to support its international clinical development strategy.